Abstract
This work elucidates the idea of finding probable critical genes linked to breast adenocarcinoma. In this study, the GEO database gene expression profile data set (GSE70951) was retrieved to look for genes that were expressed variably across breast adenocarcinoma samples and healthy tissue samples. The genes were confirmed to be part of the PPI network for breast cancer pathogenesis and prognosis. In Cytoscape, the CytoHubba module was used to discover the hub genes. For correlation analysis, the predictive biomarker of these hub genes, as well as GEPIA, was used. A total of 155 (85 upregulated genes and 70 downregulated genes) were identified. By integrating the PPI and CytoHubba data, the major key/hub genes were selected from the results. The KM plotter is employed to find the prognosis of those major pivot genes, and the outcome shows worse prognosis in breast adenocarcinoma patients. Further experimental validation will show the predicted expression levels of those hub genes. The overall result of our study gives the consequences for the identification of a critical gene to ease the molecular targeting therapy for breast adenocarcinoma. It could be used as a prognostic biomarker and could lead to therapy options for breast adenocarcinoma.
Highlights
Breast malignancy or bosom cancer is the most widely recognized sort of malignancy, among women
The GEO database is used to download the microarray data (GSE70951—Paired Breast Adenocarcinoma and Adjacent Normal Tissue). 155 differentially expressed genes were reserved into categories by functional annotation, as well as gene ontology groups. e outcome of functional enrichment analysis shows that notably differentially expressed genes were involved in the L-phenylalanine metabolic process, regulation of glial cell differentiation, L-phenylalanine catabolic process, phosphoenolpyruvate family amino acid catabolic process, and aromatic amino acid family catabolic process
From the GEPIA database, it is found that BUB1, NCAPG, CHEK1, RACGAP1, SHCBP1, SDC1, CDC7, DEPDC1, TYMS, and
Summary
Breast malignancy or bosom cancer is the most widely recognized sort of malignancy, among women. Main causes for breast cancer were hereditary predisposition, changes in hormonal levels, multifactorial, and implicated reproductive factors [1]. Bosom malignant growth is majorly caused by lifestyle changes like diet and cell phone exposure directly to the breast area, and due to hereditary changes [2, 3]. BRCA1 and BRCA2 were found to be significant genes related to hereditary breast malignancy. Cervical disease was the most widely recognized malignancy in India, and currently breast cancer is more noteworthy than cervical malignancy and turned into a main malignancy that causes ductal carcinoma in situ, obtrusive ductal carcinoma, and fiery bosom disease [5]. Under 0.2% of malignant growth-related mortality in women can Evidence-Based Complementary and Alternative Medicine be credited to breast cancer. Some of the hazardous risk factors of breast malignancy incorporate age, early menarche, childbearing, late menopause, diet, burning-through of liquor, smoking, family history, low breastfeeding for a limited period, history of premature delivery, purposeful weight reduction, chest X-beam, BMI, type 2 diabetes, bosom thickness, utilization of oral prophylactic, and chemical substitution therapy [8, 9]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Evidence-Based Complementary and Alternative Medicine
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
